Cargando…
Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy
RNA-based therapy is a promising and innovative strategy for cancer treatment. However, poor stability, immunogenicity, low cellular uptake rate, and difficulty in endosomal escape are considered the major obstacles in the cancer therapy process, severely limiting the development of clinical transla...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598637/ https://www.ncbi.nlm.nih.gov/pubmed/36290544 http://dx.doi.org/10.3390/bioengineering9100576 |
_version_ | 1784816390107037696 |
---|---|
author | Wu, Shuaiying Liu, Chao Bai, Shuang Lu, Zhixiang Liu, Gang |
author_facet | Wu, Shuaiying Liu, Chao Bai, Shuang Lu, Zhixiang Liu, Gang |
author_sort | Wu, Shuaiying |
collection | PubMed |
description | RNA-based therapy is a promising and innovative strategy for cancer treatment. However, poor stability, immunogenicity, low cellular uptake rate, and difficulty in endosomal escape are considered the major obstacles in the cancer therapy process, severely limiting the development of clinical translation and application. For efficient and safe transport of RNA into cancer cells, it usually needs to be packaged in appropriate carriers so that it can be taken up by the target cells and then be released to the specific location to perform its function. In this review, we will focus on up-to-date insights of the RNA-based delivery carrier and comprehensively describe its application in cancer therapy. We briefly discuss delivery obstacles in RNA-mediated cancer therapy and summarize the advantages and disadvantages of different carriers (cationic polymers, inorganic nanoparticles, lipids, etc.). In addition, we further summarize and discuss the current RNA therapeutic strategies approved for clinical use. A comprehensive overview of various carriers and emerging delivery strategies for RNA delivery, as well as the current status of clinical applications and practice of RNA medicines are classified and integrated to inspire fresh ideas and breakthroughs. |
format | Online Article Text |
id | pubmed-9598637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95986372022-10-27 Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy Wu, Shuaiying Liu, Chao Bai, Shuang Lu, Zhixiang Liu, Gang Bioengineering (Basel) Review RNA-based therapy is a promising and innovative strategy for cancer treatment. However, poor stability, immunogenicity, low cellular uptake rate, and difficulty in endosomal escape are considered the major obstacles in the cancer therapy process, severely limiting the development of clinical translation and application. For efficient and safe transport of RNA into cancer cells, it usually needs to be packaged in appropriate carriers so that it can be taken up by the target cells and then be released to the specific location to perform its function. In this review, we will focus on up-to-date insights of the RNA-based delivery carrier and comprehensively describe its application in cancer therapy. We briefly discuss delivery obstacles in RNA-mediated cancer therapy and summarize the advantages and disadvantages of different carriers (cationic polymers, inorganic nanoparticles, lipids, etc.). In addition, we further summarize and discuss the current RNA therapeutic strategies approved for clinical use. A comprehensive overview of various carriers and emerging delivery strategies for RNA delivery, as well as the current status of clinical applications and practice of RNA medicines are classified and integrated to inspire fresh ideas and breakthroughs. MDPI 2022-10-19 /pmc/articles/PMC9598637/ /pubmed/36290544 http://dx.doi.org/10.3390/bioengineering9100576 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wu, Shuaiying Liu, Chao Bai, Shuang Lu, Zhixiang Liu, Gang Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy |
title | Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy |
title_full | Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy |
title_fullStr | Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy |
title_full_unstemmed | Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy |
title_short | Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy |
title_sort | broadening the horizons of rna delivery strategies in cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598637/ https://www.ncbi.nlm.nih.gov/pubmed/36290544 http://dx.doi.org/10.3390/bioengineering9100576 |
work_keys_str_mv | AT wushuaiying broadeningthehorizonsofrnadeliverystrategiesincancertherapy AT liuchao broadeningthehorizonsofrnadeliverystrategiesincancertherapy AT baishuang broadeningthehorizonsofrnadeliverystrategiesincancertherapy AT luzhixiang broadeningthehorizonsofrnadeliverystrategiesincancertherapy AT liugang broadeningthehorizonsofrnadeliverystrategiesincancertherapy |